Generic Valchlor Availability
Last updated on Apr 10, 2025.
Valchlor is a brand name of mechlorethamine topical, approved by the FDA in the following formulation(s):
VALCHLOR (mechlorethamine hydrochloride - gel;topical)
-
Manufacturer: HELSINN
Approval date: August 23, 2013
Strength(s): EQ 0.016% BASE [RLD]
Is there a generic version of Valchlor available?
No. There is currently no therapeutically equivalent version of Valchlor available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Valchlor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Stabilized compositions of volatile alkylating agents and methods of using thereof
Patent 7,838,564
Issued: November 23, 2010
Inventor(s): Alonso; Robert et al.
Assignee(s): Yaupon Therapeutics Inc. (Radnor, PA)A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.
Patent expiration dates:
- March 7, 2026✓
- March 7, 2026
-
Stabilized compositions of volatile alkylating agents and methods of using thereof
Patent 7,872,050
Issued: January 18, 2011
Inventor(s): Alonso; Robert et al.
Assignee(s): Yaupon Therapeutics Inc. (Radnor, PA)A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.
Patent expiration dates:
- July 8, 2029✓
- July 8, 2029
-
Stabilized compositions of volatile alkylating agents and methods of using thereof
Patent 8,450,375
Issued: May 28, 2013
Inventor(s): Alonso Robert & Crooks Peter A. & Pimley Mark A. & Al-Ghananeem Abeer M.
Assignee(s): Ceptaris Therapeutics, Inc.A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.
Patent expiration dates:
- March 7, 2026✓
- March 7, 2026
-
Stabilized compositions of alkylating agents and methods of using same
Patent 8,501,818
Issued: August 6, 2013
Inventor(s): Alonso Robert & Stogniew Martin & Crooks Peter A. & Pimley Mark A. & Worthen David R.
Assignee(s): Ceptaris Therapeutics, Inc.Provided are stable compositions comprising alkylating agents, including nitrogen mustards, that are suitable for topical use, and methods for treating skin disorders comprising topically administering the compositions.
Patent expiration dates:
- March 7, 2026✓
- March 7, 2026
-
Stabilized compositions of volatile alkylating agents and methods of using thereof
Patent 8,501,819
Issued: August 6, 2013
Inventor(s): Alonso Robert & Crooks Peter A. & Pimley Mark A.
Assignee(s): Ceptaris Therapeutics, Inc.A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol.
Patent expiration dates:
- March 7, 2026✓
- March 7, 2026
-
Stabilized compositions of volatile alkylating agents and methods of using thereof
Patent 9,382,191
Issued: July 5, 2016
Inventor(s): Alonso Robert & Crooks Peter A. & Pimley Mark A.
Assignee(s): Actelion Pharmaceuticals, LTD.A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol.
Patent expiration dates:
- March 7, 2026✓
- March 7, 2026
More about Valchlor (mechlorethamine topical)
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.